Immunocore Presents Phase 3 Data Comparing Tebentafusp with Investigator’s Choice in the Clinical Trial Plenary Session at the American Association for Cancer Research 2021 Annual Meeting

OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, April 12 (Korea Bizwire) – Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented data from a phase 3 randomized trial [...]